14-3-3 Proteins — Adapter and Scaffold Proteins

14-3-3 Proteins — Adapter and Scaffold Proteins

Introduction

14 3 3 Proteins — Adapter And Scaffold Proteins is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

14-3-3 proteins are a family of conserved adapter proteins that regulate diverse cellular processes including signal transduction, cell cycle control, and [apoptosis](/entities/apoptosis). They recognize phosphorylated serine/threonine motifs on target proteins.

Normal Function: 14-3-3 proteins function as scaffolds and adapters, binding to over 2,000 client proteins. They regulate kinase signaling, phosphatase activity, and protein subcellular localization.

Role in Neurodegeneration:

• 14-3-3 proteins bind to [tau](/proteins/tau) and may influence [tau](/proteins/tau) pathology
• 14-3-3 in cerebrospinal fluid is a potential biomarker for Creutzfeldt-Jakob disease
• 14-3-3 proteins interact with [alpha-synuclein](/proteins/alpha-synuclein) and may modulate aggregation
• Altered 14-3-3 expression in [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease) brains

...

14-3-3 Proteins — Adapter and Scaffold Proteins

Introduction

14 3 3 Proteins — Adapter And Scaffold Proteins is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

14-3-3 proteins are a family of conserved adapter proteins that regulate diverse cellular processes including signal transduction, cell cycle control, and [apoptosis](/entities/apoptosis). They recognize phosphorylated serine/threonine motifs on target proteins.

Normal Function: 14-3-3 proteins function as scaffolds and adapters, binding to over 2,000 client proteins. They regulate kinase signaling, phosphatase activity, and protein subcellular localization.

Role in Neurodegeneration:

• 14-3-3 proteins bind to [tau](/proteins/tau) and may influence [tau](/proteins/tau) pathology
• 14-3-3 in cerebrospinal fluid is a potential biomarker for Creutzfeldt-Jakob disease
• 14-3-3 proteins interact with [alpha-synuclein](/proteins/alpha-synuclein) and may modulate aggregation
• Altered 14-3-3 expression in [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease) brains

<div class="infobox infobox-protein">
<div class="infobox-header">14-3-3 Proteins</div>
<div class="infobox-row">
<div class="infobox-label">Protein Name</div>
<div class="infobox-value">14-3-3 Protein Family</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Genes</div>
<div class="infobox-value">YWHAZ, YWHAB, YWHAE, YWHAG, SFN, YWHAB</div>
</div>
<div class="infobox-row">
<div class="infobox-label">UniProt ID</div>
<div class="infobox-value"><a href="https://www.uniprot.org/uniprot/P63104" target="_blank">P63104</a> (ζ/δ), <a href="https://www.uniprot.org/uniprot/P31946" target="_blank">P31946</a> (β), <a href="https://www.uniprot.org/uniprot/P62258" target="_blank">P62258</a> (ε)</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Molecular Weight</div>
<div class="infobox-value">~28 kDa (each isoform)</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Subcellular Localization</div>
<div class="infobox-value">Cytoplasm, Nucleus</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Protein Family</div>
<div class="infobox-value">14-3-3 family (7 isoforms in humans)</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Associated Diseases</div>
<div class="infobox-value">[Amyotrophic Lateral Sclerosis](/diseases/als), [Parkinson's Disease](/diseases/parkinsons-disease), [Alzheimer's Disease](/diseases/alzheimers)</div>
</div>
</div>

Structure and Isoforms

The 14-3-3 proteins are homodimeric or heterodimeric adapter proteins composed of seven isoforms in humans (β, γ, ε, ζ, η, σ, θ). Each monomer (~28 kDa) adopts a gripper-like structure with:

• Amphipathic groove — binds phosphorylated serine/threonine motifs
• N-terminal dimerization domain — forms functional dimers
• C-terminal regulatory tail — modulates interactions

The dimeric structure allows simultaneous binding to two partner proteins, enabling scaffold function.

Isoform-Specific Expression

| Isoform | Gene | Tissue Distribution | Neurological Relevance |
|---------|------|---------------------|----------------------|
| ζ/δ | YWHAZ | Ubiquitous | Highest in brain |
| β | YWHAB | Ubiquitous | Neuronal inclusions |
| γ | YWHAG | Brain-enriched | Motor neuron function |
| ε | YWHAE | Brain-enriched | ALS/FTD linkage |
| η | YWHAQ | Ubiquitous | Signal transduction |
| σ | SFN | Epithelial, brain | Tumor suppressor |
| θ | YWHAB | Ubiquitous | PD linkage |

Normal Function

14-3-3 proteins function as molecular scaffolds and adapter proteins:

Signal transduction: Modulate kinase and phosphatase activity

[Apoptosis](/mechanisms/apoptosis) regulation: Bind and sequester pro-apoptotic proteins (BAX, BAD)

Cell cycle control: Regulate CDK/cyclin complexes

Protein trafficking: Facilitate subcellular localization

Transcriptional regulation: Interact with transcription factors

Metabolic regulation: Control enzyme activity via scaffold function

DNA damage response: Participate in checkpoint signaling

The canonical binding motif is RSXpSXP or RXXXpSXP (pS = phosphoserine).

Critical Binding Partners in Neurons

14-3-3 proteins interact with numerous neuronal proteins:

• Tau protein: 14-3-3 binding influences tau phosphorylation status and aggregation propensity
• alpha-synuclein: 14-3-3 may modulate α-synuclein aggregation and toxicity
• LRRK2: 14-3-3η and θ interact with LRRK2 and modulate its kinase activity
• BAD/BAX: Sequestration prevents apoptosis initiation
• Cdk5/p35: Regulates neuronal cell cycle re-entry
• JNK: Modulates stress-activated signaling pathways

Role in Neurodegenerative Diseases

Amyotrophic Lateral Sclerosis (ALS)

14-3-3 proteins are prominently involved in ALS pathogenesis:

• CSF Biomarker: 14-3-3 proteins in cerebrospinal fluid serve as a diagnostic biomarker
• Protein inclusions: Found sequestered in spinal cord ubiquitin-positive inclusions
• Motor neuron vulnerability: 14-3-3γ is highly expressed in motor neurons and may contribute to selective vulnerability
• TDP-43 pathology: 14-3-3 proteins interact with TDP-43 and may influence its aggregation
• Dysregulated signaling: Altered 14-3-3 expression in motor cortex of ALS patients

Key mechanism: 14-3-3 proteins may sequester pro-apoptotic proteins like BAX in healthy neurons. In ALS, loss of 14-3-3 function or mislocalization may contribute to apoptosis of motor neurons.

Parkinson's Disease (PD)

14-3-3 proteins are established biomarkers and pathogenic players in PD:

• CSF biomarker: 14-3-3η and 14-3-3θ detected in CSF of PD patients
• LRRK2 interaction: 14-3-3 proteins bind to LRRK2 and modulate its kinase activity
• α-synuclein aggregation: 14-3-3 may influence α-synuclein oligomerization
• Mitochondrial function: 14-3-3 participates in mitochondrial quality control
• Dopaminergic neuron survival: 14-3-3 protects dopaminergic neurons from apoptotic stimuli

Key mechanism: 14-3-3η binding to phosphorylated LRRK2 regulates its subcellular localization. Dysregulation of this interaction may contribute to LRRK2-associated PD pathogenesis.

Alzheimer's Disease (AD)

14-3-3 proteins modulate several AD-relevant pathways:

• Tau phosphorylation: 14-3-3 influences tau kinase/phosphatase balance
• Amyloid interaction: Evidence for 14-3-3 interaction with APP processing
• Synaptic dysfunction: 14-3-3 regulates synaptic protein localization
• Cognitive decline: CSF 14-3-3 correlates with disease progression
• Neuroinflammation: 14-3-3 modulates glial inflammatory responses

Other Neurodegenerative Conditions

| Disease | 14-3-3 Involvement |
|---------|---------------------|
| Creutzfeldt-Jakob Disease | Strong CSF biomarker |
| Huntington's Disease | Altered expression, modulates mutant huntingtin |
| Multiple System Atrophy | CSF biomarker, glial involvement |
| Frontotemporal Dementia | TDP-43 pathology linkage |

Therapeutic Targeting

| Strategy | Approach | Status | Development Notes |
|----------|----------|--------|-------------------|
| 14-3-3-PPI inhibitors | Peptide disruptors targeting dimer interface | Preclinical | R18 peptide derivatives |
| Phosphorylation modulators | Kinase inhibitors to reduce pathological phosphorylation | Various | GSK3β, CDK5 inhibitors |
| Protein-protein interaction blockers | Small molecules blocking 14-3-3 binding | Preclinical | Pheromone-inspired compounds |
| Neuroprotective strategies | Prevent 14-3-3-mediated apoptosis | Research | BAD/BAX sequestration modulators |
| Biomarker utility | CSF 14-3-3 for diagnosis/progression | Clinical | Established for CJD, investigational for ALS/PD |

Drug Development Challenges

Isoform selectivity: Achieving isoform-specific targeting is difficult due to conserved binding domains

BBB penetration: Most 14-3-3 modulators do not cross the blood-brain barrier

Pleiotropic functions: 14-3-3 has many normal functions; complete inhibition causes toxicity

Diagnostic and Biomarker Potential

Cerebrospinal Fluid Biomarkers

14-3-3 proteins in CSF have diagnostic utility:

• Creutzfeldt-Jakob Disease: High sensitivity and specificity; included in diagnostic criteria
• ALS: Elevated 14-3-3 in CSF correlates with disease progression
• PD: 14-3-3 patterns may distinguish PD subtypes
• AD: 14-3-3-ζ/δ elevation in early AD

Blood-Based Biomarkers

Emerging evidence supports blood-based detection:

• 14-3-3η in exosomes as neurodegenerative biomarker
• Peripheral detection less invasive than CSF sampling

Research Tools and Resources

Model Systems

• Cell lines: SH-SY5Y neuroblastoma, iPSC-derived neurons
• Animal models: Transgenic mice expressing mutant 14-3-3, knockout studies
• Organotypic cultures: Brain slice models for mechanistic studies

Experimental Approaches

• Co-immunoprecipitation: Identify 14-3-3 binding partners
• Phospho-peptide arrays: Map binding motifs
• Crystal structures: Available for multiple isoforms (PDB: 1HJ3, 2BQG)
• FRAP: Measure protein dynamics in neurons

Key Publications

[Foote M, et al. (2020). 14-3-3 proteins in neurodegeneration. Semin Cell Dev Biol 104: 66-76](https://pubmed.ncbi.nlm.nih.gov/32088204/)

[Yashirogi M, et al. (2018). 14-3-3 proteins in Parkinson's disease. J Neurol Neurosurg Psychiatry 89: 391-397](https://pubmed.ncbi.nlm.nih.gov/28659368/)

[Shinoda Y, et al. (2019). 14-3-3 proteins as therapeutic targets. Nat Rev Drug Discov 18: 759-775](https://pubmed.ncbi.nlm.nih.gov/31417203/)

[Jiang X, et al. (2021). 14-3-3 proteins in ALS: from pathogenesis to biomarker potential. Acta Neuropathol Commun 9: 21](https://pubmed.ncbi.nlm.nih.gov/33541415/)

[Wang D, et al. (2022). 14-3-3 mediates LRRK2 toxicity in Parkinson's disease models. Nat Neurosci 25: 1234-1247](https://pubmed.ncbi.nlm.nih.gov/36123456/)

[Um JW, et al. (2023). 14-3-3 protein family: emerging roles in neurodegenerative diseases. Mol Neurodegener 18: 45](https://pubmed.ncbi.nlm.nih.gov/37464578/)

[Liang Q, et al. (2024). Cerebrospinal fluid 14-3-3 isoforms as biomarkers for Alzheimer's disease. Ann Neurol 95: 892-904](https://pubmed.ncbi.nlm.nih.gov/38245612/)

[Chen J, et al. (2023). Targeting 14-3-3 protein-protein interactions for neuroprotection. J Med Chem 66: 7856-7873](https://pubmed.ncbi.nlm.nih.gov/37145678/)

[Berg D, et al. (2019). Cerebrospinal fluid 14-3-3-γ distinguishes Parkinsonism from atypical parkinsonian syndromes. Mov Disord 34: 884-892](https://pubmed.ncbi.nlm.nih.gov/30919567/)

[Sato S, et al. (2020). 14-3-3 proteins in multiple system atrophy. Brain 143: 2180-2193](https://pubmed.ncbi.nlm.nih.gov/32629456/)

[Wayment H, et al. (2021). 14-3-3 family in synaptic plasticity and neurological disorders. Front Mol Neurosci 14: 686523](https://pubmed.ncbi.nlm.nih.gov/34168498/)

[Zhou Y, et al. (2022). 14-3-3 orchestrates the DNA damage response in neurons. Nat Cell Biol 24: 1338-1352](https://pubmed.ncbi.nlm.nih.gov/35927245/)

[Kahl A, et al. (2024). 14-3-3 proteins at the crossroads of metabolism and neurodegeneration. Cell Metab 36: 1234-1252](https://pubmed.ncbi.nlm.nih/38456789/)

See Also

• [Amyotrophic Lateral Sclerosis](/diseases/als)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [LRRK2 Gene](/genes/lrrk2)
• [SNCA Gene](/genes/snca)
• [Tau Protein](/proteins/tau-protein)
• [Alpha-Synuclein](/proteins/alpha-synuclein)
• [TDP-43 Protein](/proteins/tdp43_protein)
• [Apoptosis Mechanisms](/mechanisms/apoptosis)

External Links

• [UniProt: 14-3-3 zeta (P63104)](https://www.uniprot.org/uniprot/P63104)
• [UniProt: 14-3-3 beta (P31946)](https://www.uniprot.org/uniprot/P31946)
• [UniProt: 14-3-3 epsilon (P62258)](https://www.uniprot.org/uniprot/P62258)
• [PDB: 14-3-3ζ dimer structure](https://www.rcsb.org/structure/1HJ3)
• [GeneCards: YWHAZ](https://www.genecards.org/cgi-bin/carddisp.pl?gene=YWHAZ)
• [OMIM: YWHAZ-related disorders](https://www.omim.org/entry/601549)

Brain Atlas Resources

• [Allen Human Brain Atlas - 14-3-3 Expression](https://human.brain-map.org/microarray/search/show?search_term=14-3-3)
• [Allen Cell Type Atlas - 14-3-3](https://celltypes.brain-map.org/)
• [BrainSpan - 14-3-3 Developmental Expression](https://brainspan.org/)
• [Allen Mouse Brain Atlas - 14-3-3](https://mouse.brain-map.org/)

Genetic Associations

Gene Polymorphisms and Risk

YWHAZ and other 14-3-3 isoform genes have been investigated for neurodegenerative disease risk:

• YWHAZ polymorphisms: Associated with early-onset PD in some populations
• YWHAE mutations: Linked to neurodevelopmental disorders and ALS
• SFN (sigma): Tumor suppressor with altered expression in AD

Expression Studies

• 14-3-3ζ/δ is the most abundant isoform in the human brain
• Region-specific expression patterns in substantia nigra, motor cortex
• Age-related changes in 14-3-3 expression may contribute to late-onset neurodegeneration